Refractory Plasma Cell Myeloma
Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma
TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses